Category: Lab Top-10
PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company
Enters agreement with intention to divest Applied, Food and Enterprise Services businesses WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital,... Read more
Thermo Fisher Scientific Reports Second Quarter 2022 Results
WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 2, 2022. Second Quarter 2022 Highlights Second quarter revenue was $10.97 billion. Second quarter GAAP diluted earnings per share (EPS) was $4.22. Second quarter adjusted EPS was $5.51. Delivered... Read more
Two PerkinElmer Tests Added to UK’s Updated NICE Diagnostic Guidance for Suspected Preterm Pre-Eclampsia
WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom’s National... Read more
PerkinElmer Elects Dr. Michelle McMurry-Heath to its Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 22, 2022– PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Dr. Michelle McMurry-Heath has been elected to its board of directors, effective July 22, 2022. “I am pleased to welcome Michelle to PerkinElmer’s board and excited to see the Company benefit from both her... Read more
Danaher Reports Second Quarter 2022 Results
WASHINGTON, D.C., July 21, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the second quarter 2022. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended July 1, 2022, net earnings were $1.7 billion, or $2.25 per diluted common share which represents a 1.5%... Read more
PerkinElmer Schedules Earnings Call for Thursday, August 4, 2022
WALTHAM, Mass.–(BUSINESS WIRE)–Jul. 14, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022 at 6:00 a.m. ET. The Company will host a conference call the same day at 8:00 a.m. ET... Read more
PerkinElmer Streamlines Flow Cytometry Management For Biopharmaceutical Labs with New OneSource Concierge Service
WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added PerkinElmer Flow Cytometry Instrument Concierge Services to its OneSource® Laboratory Services portfolio. The comprehensive and flexible offering will provide biopharmaceutical labs with expert, onsite flow cytometry specialists to help manage their instruments and processes more efficiently... Read more
Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research
Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets UTRECHT, The Netherlands–(BUSINESS WIRE)– At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHzNMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend Evo... Read more
Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment
ETTLINGEN, Germany–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today has launched PhenoRiskPACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson. The PhenoRiskPACS™ RuO test is promising for research... Read more